[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569334":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":28,"responsibleParty":48,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":10,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"University of Vermont","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Adults with Myelodysplastic syndromes",null,"All participants will be in one group. Participants will by adults with Myelodysplastic syndromes. Blood will be taken at regular appointments that are part of standard care.",[13],"Other: Observational",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Observational","Blood will be collected from one cohort to identify potential blood biomarkers.",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Diego Adrianzen Herrera, MD","CONTACT","(802) 656-2021","dadrianz@med.uvm.edu",{"name":26,"role":22,"phone":23,"phoneExt":10,"email":27},"Neil A Zakai, MD","neil.zakai@med.uvm.edu",[29],{"facility":5,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Burlington","Vermont","05495-2038","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-73.21207,44.47588,{"lat":40,"lon":39},[43,46],{"name":21,"role":22,"phone":44,"phoneExt":10,"email":45},"(802) 656-4414","dadrianz@uvm.edu",{"name":21,"role":47,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":47,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Diego Adrianzen Herrera","Medical Oncologist, Assistant Professor","100569334","defining-inflammatory-markers-of-cardiovascular-disease-in-patients-with-myelodysplastic-syndromes-100569334",false,"NCT06692894","Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes","Defining Inflammatory Biomarkers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes","Inclusion Criteria:\n\n* Age ≥18 years\n* Histologically confirmed diagnosis of MDS by bone marrow biopsy morphology, using the 2022 World Health Organization (WHO) classification for myeloid neoplasms\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤3\n* Expected survival of at least 6 months\n* Ability to provide consent\n\nExclusion Criteria:\n\n* Cases meeting 2022 WHO criteria of MDS with excess blasts 2 as initial diagnosis\n* Hematopoietic stem cell transplantation expected within 6 months","ALL","18 Years",{"count":61,"type":62},30,"ESTIMATED","OBSERVATIONAL","Why Is This Research Study Being Conducted?\n\n* The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are more likely to have heart problems like heart disease and stroke.\n* Researchers also want to see if certain proteins related to inflammation in the body can help predict these heart issues in MDS patients.\n* By understanding this better, researchers hope to find new ways to detect and manage heart disease risks in people with MDS",[66],"Myelodysplastic Syndromes, Adult",[68,69],"Myelodysplastic Syndromes","Hematology","2026-02-02",{"date":72,"type":73},"2026-02-03","ACTUAL",{"date":75,"type":73},"2024-11-05",{"date":77,"type":62},"2027-11",{"name":5,"class":6},1]